Last reviewed · How we verify
ALXN1210 IV
ALXN1210 is a C5 complement inhibitor that blocks the terminal complement cascade.
ALXN1210 is a C5 complement inhibitor that blocks the terminal complement cascade. Used for Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS).
At a glance
| Generic name | ALXN1210 IV |
|---|---|
| Also known as | Ravulizumab, Ultomiris |
| Sponsor | Alexion Pharmaceuticals, Inc. |
| Drug class | Complement inhibitor |
| Target | C5 |
| Modality | Small molecule |
| Therapeutic area | Rare Disease |
| Phase | Phase 1 |
Mechanism of action
By inhibiting the C5 complement protein, ALXN1210 prevents the formation of the membrane attack complex (MAC), which is responsible for the destruction of cells in certain diseases.
Approved indications
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Atypical hemolytic uremic syndrome (aHUS)
Common side effects
- Headache
- Nausea
- Upper respiratory tract infection
Key clinical trials
- Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation (PHASE3)
- Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) (PHASE3)
- A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works (PHASE3)
- Study of Ravulizumab in Pediatric Participants With Primary IgAN (PHASE3)
- A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment (PHASE3)
- Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG) (PHASE3)
- Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS (PHASE4)
- Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALXN1210 IV CI brief — competitive landscape report
- ALXN1210 IV updates RSS · CI watch RSS
- Alexion Pharmaceuticals, Inc. portfolio CI